The US FDA should consider establishing dedicated mechanisms for discussing and submitting patient experience data, industry representatives and patient groups said in comments on the agency's patient-focused drug development (PFDD) initiative.
FDA also should clarify how it intends to use such data in regulatory decision-making and where such data may
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?